लोड हो रहा है...
Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu(3)ManNAc, a “metabolic glycoengineering” drug candidate that increased sialylation by ∼12-fold. Consistent wi...
में बचाया:
| में प्रकाशित: | Bioorg Med Chem Lett |
|---|---|
| मुख्य लेखकों: | , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2015
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5753412/ https://ncbi.nlm.nih.gov/pubmed/25690786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2015.01.060 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|